Given the antigenic similarity between cancer and embryonic tissues [81] and the capability of gp96 to bind the entire peptide repertoire generated within the cell [82], there is a rational basis for the use of placenta-derived gp96 as a multivalent prophylactic cancer vaccine. Here, HSP90B1 is linked to cancer.